|
||||||||||||||||
|
||||||||||||||||
The following HTML text is provided to enhance online readability. Many aspects of typography translate only awkwardly to HTML. Please use the page image as the authoritative form to ensure accuracy. Spear BB, Heath-Chiozzi M, Huff J. 2001. Clinical application of pharmacogenetics. Trends in Molecular Medicine 7(5):201-204. Srivastava S, Wagner J. 2002. Surrogate endpoints in medicine. Disease Markers 18:39-40. Stearns V, Johnson MD, Rae JM, Morocho A, Novielli A, Bhargava P, Hayes DF, Desta Z, Flockhart DA. 2003. Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine. Journal of the National Cancer Institute 95(23):1758-1764. Stoughton RB, Friend SH. 2005. How molecular profiling could revolutionize drug discovery. Nature Reviews Drug Discovery 4(4):345-350. Tinker AV, Boussioutas A, Bowtell DD. 2006. The challenges of gene expression microarrays for the study of human cancer. Cancer Cell 9(5):333-339. TSC (The SNP Consortium). 2006. The SNP Consortium Ltd. [Online]. Available: http://snp.cshl.org [accessed June 2006]. Tyers M, Mann M. 2003. From genomics to proteomics. Nature 422(6928):193-197. van der Greef J, McBurney RN. 2005. Innovation: Rescuing drug discovery: in vivo systems pathology and systems pharmacology. Nature Reviews Drug Discovery 4(12):961-967. Varmus H. 2006. The new era in cancer research. Science 312(5777):1162-1165. Wagner JA. 2002. Overview of biomarkers and surrogate endpoints in drug development. Disease Markers 18(2):41-46. Wagner, JA. 2006, March 20. Biomarker Validation and Qualification: Fitness for Use. Presentation at the IOM workshop on Developing Biomarker-based Tools for Cancer Screening, Diagnosis, and Treatment. Washington, DC. Weckwerth W, Morgenthal K. 2005. Metabolomics: from pattern recognition to biological interpretation. Drug Discovery Today 10(22):1551-1558. Yezhelyev MV, Gao X, Xing Y, Al-Hajj A, Nie S, O’Regan RM. 2006. Emerging use of nanoparticles in diagnosis and treatment of breast cancer. Lancet Oncology 7(8):657-667. Young S. 2006. MMRC Executive Director. Personal Communication. June 7, 2006. Zolg JW, Langen H. 2004. How industry is approaching the search for new diagnostic markers and biomarkers. Molecular and Cellular Proteomics 3(4):345-354.
|
|
|||||||||||||||
